Ignite Creation Date:
2024-10-26 @ 3:37 PM
Last Modification Date:
2024-10-26 @ 3:37 PM
Study NCT ID:
NCT06551246
Status:
RECRUITING
Last Update Posted:
None
First Post:
2024-06-25
Brief Title:
Efficacy of Solifenacin Mirabegron and Combination Therapy in Children with Daytime Urinary Incontinence BeDry
Sponsor:
None
Organization:
None
Study Overview
Official Title:
Efficacy of Solifenacin Mirabegron and Combination Therapy in Children with Overactive Bladder and Daytime Urinary Incontinence BeDry
Status:
RECRUITING
Status Verified Date:
2024-06
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The primary objective is to evaluate if 1 combination therapy of solifenacin and mirabegron in low doses is superior to monotherapy of solifenacin in high dose and if 2 combination therapy of mirabegron and solifenacin in low doses is superior to monotherapy of mirabegron in high dose in treatment of daytime urinary incontinence among children aged 5 to 14 years who are none complete responders to respectively monotherapy of solifenacin in low dose or monotherapy of mirabegron in low dose
In total 236 children diagnosed with daytime urinary incontinence will be randomized 1111 to one of four treatment groups Total pharmacological treatment period will be 18 weeks
In total 236 children diagnosed with daytime urinary incontinence will be randomized 1111 to one of four treatment groups Total pharmacological treatment period will be 18 weeks
Detailed Description:
Background According to International Childrens Continence Society first-line treatment of children with daytime urinary incontinence is standard urotherapy eventually followed by pharmacotherapy of anticholinergics The effect of medical treatment is sparsely investigated and primarily in non-randomized trials
Objectives The primary objective is to evaluate if 1 combination therapy of solifenacin and mirabegron in low doses is superior to monotherapy of solifenacin in high dose and if 2 combination therapy of mirabegron and solifenacin in low doses is superior to monotherapy of mirabegron in high dose in treatment of daytime urinary incontinence among children aged 5 to 14 years who are none complete responders to respectively monotherapy of solifenacin in low dose or monotherapy of mirabegron in low dose
The secondary objective is to evaluate the treatment response of combination therapy of solifenacin and mirabegron in low doses monotherapy in high dose and monotherapy in low doses as supplementary comparisons Additionally the secondary objective is to evaluate side effects safety and tolerability of the medical treatment as well as the effect of treatment on well-being and quality of life
Study design The BeDry study is designed as a multicenter randomized single-blinded controlled clinical trial Included children will be randomized 1111 to one of four treatment groups Children aged 5-14 years diagnosed with daytime urinary incontinence refractory to standard urotherapy will be randomized Initially two groups will receive solifenacin 5 mg and two groups will receive mirabegron 25 mg After 6 weeks non-complete respondsers will receive add-on treatment according to their primary randomization group group 1A will reviece solifenacin 5 mg and add-on solifenacin 5 mg group 1B will receive solifenacin 5 mg and add-on mirabegron 25 mg group 2A will receive mirabegron 25 mg and add-on mirabegron 25 mg group 2B will receive mirabegron 25 mg and add-on solifenacin 5 mg Total treatment period will be 18 weeks The primary endpoint measure is treatment response assessed by change from visit 2 to end of study according to number of wet days pr 7 days by DryPie
Perspectives The trial has the potential to optimize medical treatment of children with daytime urinary incontinence to shorten the treatment period diminish side effects and minimized unnecessary medical expenses
Ethics All pharmacological side effects will be handled in accordance with the Danish legislation No risk or unknown side effects are expected to urotherapy medical treatment or withdrawal No risks are expected by the clinical examination and paraclinical measurements The therapeutic potential for future patients justifies the project to be carried out Participation in this study will not lead to any disadvantages for the patient in their treatment The study will be conducted in accordance with the protocol applicable regulatory requirements according to Good Clinical Practice and the ethical principles of the Declaration of Helsinki The study is approved by the authorities Significant additions or changes to the protocol may be conducted after the application for amendment is approved by the Regulatory Authority and the Ethics Committee Information regarding the participants is protected according to the General Data Protection Regulation and the actual law The study is registered at the research inventory of the Regions of Denmark 1-16-02-210-24 and at Aarhus University ARG-2024-731-23829 The study is registered and authorized at CTIS EU CT 2023-510187-13-00
Objectives The primary objective is to evaluate if 1 combination therapy of solifenacin and mirabegron in low doses is superior to monotherapy of solifenacin in high dose and if 2 combination therapy of mirabegron and solifenacin in low doses is superior to monotherapy of mirabegron in high dose in treatment of daytime urinary incontinence among children aged 5 to 14 years who are none complete responders to respectively monotherapy of solifenacin in low dose or monotherapy of mirabegron in low dose
The secondary objective is to evaluate the treatment response of combination therapy of solifenacin and mirabegron in low doses monotherapy in high dose and monotherapy in low doses as supplementary comparisons Additionally the secondary objective is to evaluate side effects safety and tolerability of the medical treatment as well as the effect of treatment on well-being and quality of life
Study design The BeDry study is designed as a multicenter randomized single-blinded controlled clinical trial Included children will be randomized 1111 to one of four treatment groups Children aged 5-14 years diagnosed with daytime urinary incontinence refractory to standard urotherapy will be randomized Initially two groups will receive solifenacin 5 mg and two groups will receive mirabegron 25 mg After 6 weeks non-complete respondsers will receive add-on treatment according to their primary randomization group group 1A will reviece solifenacin 5 mg and add-on solifenacin 5 mg group 1B will receive solifenacin 5 mg and add-on mirabegron 25 mg group 2A will receive mirabegron 25 mg and add-on mirabegron 25 mg group 2B will receive mirabegron 25 mg and add-on solifenacin 5 mg Total treatment period will be 18 weeks The primary endpoint measure is treatment response assessed by change from visit 2 to end of study according to number of wet days pr 7 days by DryPie
Perspectives The trial has the potential to optimize medical treatment of children with daytime urinary incontinence to shorten the treatment period diminish side effects and minimized unnecessary medical expenses
Ethics All pharmacological side effects will be handled in accordance with the Danish legislation No risk or unknown side effects are expected to urotherapy medical treatment or withdrawal No risks are expected by the clinical examination and paraclinical measurements The therapeutic potential for future patients justifies the project to be carried out Participation in this study will not lead to any disadvantages for the patient in their treatment The study will be conducted in accordance with the protocol applicable regulatory requirements according to Good Clinical Practice and the ethical principles of the Declaration of Helsinki The study is approved by the authorities Significant additions or changes to the protocol may be conducted after the application for amendment is approved by the Regulatory Authority and the Ethics Committee Information regarding the participants is protected according to the General Data Protection Regulation and the actual law The study is registered at the research inventory of the Regions of Denmark 1-16-02-210-24 and at Aarhus University ARG-2024-731-23829 The study is registered and authorized at CTIS EU CT 2023-510187-13-00
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None